Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV. Issue 4 (8th March 2021)

• Record Type: Journal Article
• Authors: Hirt, Déborah; Kubota Kilengelela, Jean; Jarreau, Pierre-Henri; Tréluyer, Jean-Marc; Marcou, Valérie
• Is Part Of: Pediatric infectious disease journal. Volume 40:Issue 4(2021)
• Page Start: 344
• Page End: 346
• Publication Date: 2021-03-08
• Subjects: prevention of mother-to-child transmission of HIV -- nevirapine -- preterm newborn; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000002994
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : Eleven newborns from 25 to 32 weeks of gestational age, weighting from 0.66 to 1.60 kg received 2 mg/kg doses of nevirapine syrup. In 15 samples, collected 8.75–89 hours after drug intake, concentrations ranged from 0.65 to 16.68 mg/L. Three nevirapine dose of 2 mg/kg at day 0, 2 and 6 days of life achieved nevirapine concentrations above the proposed nevirapine target for HIV prophylaxis for at least 11 days.